New Late-Breaking Results from Phase 3 Trials of SKYRIZI

/PRNewswire/ -- AbbVie (NYSE: ABBV) announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials evaluating SKYRIZI® (risankizumab, 150 mg) in...

Related Keywords

Milan , Lombardia , Italy , Sweden , Denmark , Copenhagen , Køavn , Doina Cosma Roman , Lars Erik Kristensen , Clin Rheumatol , European Academy Of Dermatology , Instagram , Abbvie Ltd , Linkedin , Twitter , Venereology Virtual Congress , Boehringer Ingelheim , American College Of Rheumatology , Allergan , Abbvie Inc , Facebook , University Hospital In Lund , Parker Institute , Clinical Development , Exchange Commission , Youtube , Psoriasis Area , Severity Index , American College , European Academy , Hybrid Congress , Global Assessment , Fingernail Psoriasis , Nail Psoriasis Severity Index , Important Safety Information , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Active Psoriatic Arthritis , Week Results , Week Results From , Venereology Virtual , Including Patients With Inadequate Response , Biologic Therapies , Pract Res Clin , Accessed August , Study Comparing Risankizumab , Subjects With Active Psoriatic Arthritis , Who Have , Inadequate Response , Least One Disease Modifying Anti Rheumatic Drug , Double Blind Study Comparing Risankizumab , Biologic Therapy , Placebo Controlled Induction Study , Severely Active Ulcerative , Abbvie ,